Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 17 January 2026
2019-01-09 07:33:00 Wednesday ET

Apple revises down its global sales revenue estimate to $83 billion due to subpar smartphone sales in China. Apple CEO Tim Cook points out the fact that he
2018-09-27 11:41:00 Thursday ET

Michael Kors pays $2.3 billion to acquire the Italian elite fashion brand Versace. In accordance with Michael Kors's 5-year plan, the joint company grow
2023-05-07 10:27:00 Sunday ET

William Easterly critiques several economic development policies and then indicates that bottom-up solutions often result in macro policy success in spite o
2017-10-09 09:34:00 Monday ET

The current Trump stock market rally has been impressive from November 2016 to October 2017. S&P 500 has risen by 21.1% since the 2016 presidential elec
2017-06-09 06:37:00 Friday ET

To complement President Trump's pro-business economic policies such as low taxation, new infrastructure, greater job creation, and technological in
2017-03-27 06:33:00 Monday ET

Goldman Sachs chief economist Jan Hatzius says the Federal Reserve's QE exit strategy makes sense ahead of Fed Chair Janet Yellen's stepdown in 2018